(CercleFinance.com) – Sanofi reports positive data in the context of a second phase III trial evaluating its Dupixent in COPD (chronic obstructive pulmonary disease), results which make it possible to accelerate the submission to the FDA of the United States- United, according to the health giant.
The NOTUS trial indeed achieved its primary endpoint with a significant reduction in exacerbations of 34%, compared to placebo, in patients with moderate to severe form of COPD with type 2 inflammation.
Dupixent achieved rapid and significant improvement in respiratory function, compared to placebo, at week 12. Submission of a supplemental biologics license application is anticipated before the end of 2023.